Free Trial
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

IDEXX Laboratories logo
$452.89 +1.90 (+0.42%)
Closing price 02/20/2025 03:59 PM Eastern
Extended Trading
$452.56 -0.33 (-0.07%)
As of 02/20/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IDEXX Laboratories Stock (NASDAQ:IDXX)

Key Stats

Today's Range
$450.39
$457.70
50-Day Range
$408.85
$469.04
52-Week Range
$398.50
$583.39
Volume
615,712 shs
Average Volume
704,594 shs
Market Capitalization
$37.09 billion
P/E Ratio
42.45
Dividend Yield
N/A
Price Target
$533.75
Consensus Rating
Moderate Buy

Company Overview

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

IDXX MarketRank™: 

IDEXX Laboratories scored higher than 91% of companies evaluated by MarketBeat, and ranked 91st out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IDEXX Laboratories has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about IDEXX Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEXX Laboratories are expected to grow by 13.83% in the coming year, from $11.93 to $13.58 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEXX Laboratories is 42.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.09.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEXX Laboratories is 42.45, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.91.

  • Price to Earnings Growth Ratio

    IDEXX Laboratories has a PEG Ratio of 3.38. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IDEXX Laboratories has a P/B Ratio of 23.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about IDEXX Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    2.42% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently increased by 13.29%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    IDEXX Laboratories does not currently pay a dividend.

  • Dividend Growth

    IDEXX Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.42% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently increased by 13.29%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    IDEXX Laboratories has a news sentiment score of 1.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 23 news articles for IDEXX Laboratories this week, compared to 11 articles on an average week.
  • Search Interest

    14 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,161,276.00 in company stock.

  • Percentage Held by Insiders

    Only 2.11% of the stock of IDEXX Laboratories is held by insiders.

  • Percentage Held by Institutions

    87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEXX Laboratories' insider trading history.
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

Three new patents reveal Elon and Trump’s secret “Project America”
Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.
See More Headlines

IDXX Stock Analysis - Frequently Asked Questions

IDEXX Laboratories' stock was trading at $413.44 at the start of the year. Since then, IDXX stock has increased by 9.5% and is now trading at $452.8910.
View the best growth stocks for 2025 here
.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings data on Thursday, October, 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories's revenue was up 6.6% on a year-over-year basis.
Read the conference call transcript
.

Top institutional shareholders of IDEXX Laboratories include Vanguard Group Inc. (11.86%), Fundsmith LLP (3.25%), Geode Capital Management LLC (2.81%) and Bamco Inc. NY (2.45%). Insiders that own company stock include Jonathan W Ayers, Jonathan Jay Mazelsky, Brian P Mckeon, James F Polewaczyk, George Fennell, Kathy V Turner, Michael Lane, M Anne Szostak, Daniel M Junius, Sophie V Vandebroek and Bruce L Claflin.
View institutional ownership trends
.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

Last Earnings
10/31/2024
Today
2/21/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
11,000
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$533.75
High Stock Price Target
$580.00
Low Stock Price Target
$500.00
Potential Upside/Downside
+17.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$887.87 million
Pretax Margin
28.48%

Debt

Sales & Book Value

Annual Sales
$3.90 billion
Cash Flow
$11.44 per share
Book Value
$19.48 per share

Miscellaneous

Free Float
80,157,000
Market Cap
$37.09 billion
Optionable
Optionable
Beta
1.37

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:IDXX) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners